EnteroMedics Inc (NASDAQ:ETRM)
EnteroMedics Inc (NASDAQ:ETRM) stock was up over 17% in Monday’s after-hours trading session, to end at $4.49, after the company announced a loss of $6.8 million in its second quarter. Revenues came in at $93,000 – less than what was expected. However, on a per-share basis, the St. Paul, MN-based, medical device company lost (-$0.91) which beat street estimates by $0.02.
Importantly, implantations of the company’s lead revenue generator, the vBloc®, was up over 83% from the same quarter last year. For the six months ended June 30, 2017, the Company placed 50 units, primarily from the vBloc Now program, a 72% increase compared to 29 units for the same period in 2016. As of June 30, 2017, the Company had cash, cash equivalents and short-term investments totaling $11.2 million and it had no debt.
EnteroMedics Inc (NASDAQ:ETRM) is a developer of medical devices that cater to the weight-loss market. The company developed the FDA-approved vBloc® neurometabolic therapy. The vBloc® therapy is delivered by a pacemaker-like device called the Maestro® Rechargeable System. This device is designed to help patients feel full and eat less by intermittently blocking hunger signals on the vagus nerve – thereby allowing patients to safely lose weight by helping patients feel less hungry, reduce the amount of food eaten at a meal, and feel full longer in between meals. The vBloc® Therapy is a non-anatomy altering or restricting, and is reversible. therapy that allows patients to safely lose weight by helping patients feel less hungry, reduce the amount of food eaten at a meal, and feel full longer in between meals.
Bariosurge Inc. was recently acquired by EnteroMedics Inc (NASDAQ:ETRM) which gave the company an additional revenue stream originating from the weight-loss market. Bariosurge is the developer of the Gastric Vest System™. The Gastric Vest is being developed as a minimally invasive, laparoscopically implanted medical device for weight loss in morbidly obese patients. The device wraps around the stomach, emulating the effect of conventional weight-loss surgery, and is intended to reduce the size of the stomach without permanently changing one’s anatomy.
EnteroMedics Inc (NASDAQ:ETRM) continues to address the primary cause of drag on the stock price – a lack of coverage by major insurance companies. It is important to remember that the stock blasted over 700% on the news that the company had two new facilities agree to be used for device implantation. It appears the market will reward the company for any advancement of its device into the medical mainstream.
I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.
Don’t miss out! Stay informed on $ETRM and receive breaking news on other hot stocks by signing up for our free newsletter!
About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.